Multifunctional liposomes (mf-LIPs) having a curcumin-lipid ligand (to target amyloids) together with two ligands to target the transferrin, and the low-density apolipoprotein receptor of the blood-brain-barrier (BBB) on their surface, were previously studied (in vitro) as potential theranostic systems for Alzheimer's disease (AD) (Papadia et al., 2017, Eur. J. Pharm. Sciences; 101:140-148). Herein, the targeting potential of mf-LIPs was compared to that of BBB-LIPs (liposomes having only the two BBB-specific ligands) in FVB mice (normal), as well as in double transgenic mice (APP/PS1) and their corresponding littermates (WT), by live-animal (in vivo) and explanted organ (ex vivo) imaging. In FVB mice, the head-signals of mf-LIPs and BBB-LIPs are either similar, or signals from mf-LIP are higher, suggesting that the co-presence of the curcumin derivative on the liposome surface does not disturb the functionality of the BBB-specific ligands. Higher brain / liver + spleen ratios (ex vivo) were calculated post-injection of mf-LIP, compared to those found after BBB-LIP injection, due to the reduced distribution of mf-LIPs in the liver and spleen; showing that the curcumin ligand increases the stealth properties of liposomes by reducing their uptake by liver and spleen. The later effect is more pronounced when the density of the BBB-specific ligands on the mf-LIPs is 0.1 mol%, compared to 0.2%, highlighting the importance of this parameter. When a high lipid dose (4 mg/mouse) is injected in WT and APP/PS1 mice, the headsignals of mf-LIPs are significantly higher than those of BBB-LIPs, but no differences are observed between WT and APP/PS1 mice. However, after administration of a low liposome dose (0.05 mg/mouse) of mf-LIPs, significant differences in the head-signals are found between WT and transgenic mice, highlighting the AD theranostic potential of the multifunctional liposomes, as well as the importance of the experimental parameters used in such in vivo screening studies.
Introduction
As the blood-brain barrier (BBB) is an unresolved challenge for therapy/diagnosis of brain-located pathologies (Coureuil et al., 2017; Pardridge, 2012) , non-invasive nanotechnology-assisted approaches have been proposed as potential diagnostic and/or therapeutic systems for Alzheimer's disease (AD) Ma et al., 2015) . In this context, we have recently developed multifunctional LUV liposomes (mf-LIPs) with potential to target both, the BBB and the (brain located) amyloid deposits; the final aim being to understand if such multifunctional nanoparticles having more than one targeting ligands on their surface, can preserve their multiple functionalities (Papadia et al., 2017) . The mf-LIPs developed consist of a PEGylated liposome core, onto which three different ligands are immobilized, a lipid-derivative of curcumin (TREG) with high affinity for amyloid deposits Taylor et al., 2011) , and two ligands to target the brain, a monoclonal antibody against the transferrin receptor (TfRMab) Pardridge, 2016) and a peptide derivative of apolipoprotein E (ApoE) with affinity for the low-density apolipoprotein receptor . The dual-ligand-decorated BBB targeting liposomes (with TfR-Mab plus ApoE on their surface), referred to as BBB-LIPs, were previously found to further enhance the BBB targeting potential of LIPs when immobilized on the same vesicle, compared to the two corresponding vesicle types (TfR-Mab-LIPs and ApoE-LIPs), having any one ligand on their surface , in in vitro and in vivo studies.
The hCMEC/D3 monolayer, was used as a cellular model of the BBB in our previous studies, although it forms a rather "leaky" barrier compared to cellular models consisted of primary endothelial cells or co-cultures of endothelial cells with other cell types (i.e. astrocytes), since it was proven to be a good model for comparative screening of different types of formulations. Indeed, when PEG-LIPs (with no ligands), ApoE-LIPs (with only ApoE), TfR-Mab-LIPs (with only TfR-Mab) and BBB-LIPs were studied under identical conditions , the BBB-LIPs demonstrated significantly higher permeability across the monolayer, compared to all the control liposomes, regardless of their larger size, which should result in lower permeation if the permeation was related to the leakiness of the barrier. Also, both liposome types with only one ligand on their surface (ApoE-LIPs and TfR-MabLIPs), demonstrated higher permeability compared to PEG-LIPs. In vivo and ex vivo imaging studies, provided additional confirmation of the comparative targeting potential of the different formulations.
Furthermore, in a recent study by Papadia et al. (2017) , the current mf-LIPs were evaluated in vitro for their ability to inhibit Aβ peptide aggregation and to translocate across hCMEC/D3 monolayers, and it was proven that the presence of the three ligands on the surface of the vesicles did not disturb any of their functions. Also, a preliminary in vivo live animal imaging study was carried out, which verified the in vitro findings.
Herein, extended in vivo live animal imaging studies were performed in normal FVB mice injected with mf-LIPs, in order to verify the results of the preliminary in vivo study (Papadia et al., 2017) , and also to evaluate the effect of the liposome dose, and the surface density of the BBB-specific ligands immobilized on liposomes, on the liposome targeting potential. Ex vivo measurements of explanted organs (brain, liver and spleen) were carried out in some cases, for confirmation of the in vivo imaging values. Finally, in vivo imaging studies were also performed in double transgenic mice (APP/PS1) and their wild type littermates (WT), as a preliminary investigation of the targeting potential of such mf-LIPs in an animal model of Alzheimer's disease. -Mal] and lissamine rhodamine B phosphatidylethanolamine [RHO-lipid] were purchased from Avanti Polar Lipids. Sephadex G-50 and Sepharose 4B-CL, were from Sigma-Aldrich. Anti-mouse CD71 IgG2a (clone RI7217), which was used in all the in vivo studies carried out herein, as well as the preliminary in vivo study reported earlier (Papadia et al., 2017) , replacing the OX-26 clone used in the studies with human cells, was from Biolegend. Amicon-Ultra 15 tubes (Millipore) were used for sample concentration. All other chemicals were obtained from Merck. Lipophilic tracer 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbo cyanine iodide (DiR; Molecular Probes) was used as a liposome label for live animal imaging. Human ApoE peptide (141-150) (ApoE) with a tryptophan residue at the C-terminal (for fluorescence detection), and a cysteine residue at the N-terminal (to aid immobilization on the surface of PEG-MAL functionalized LIPs), were kindly provided by Dr. Mario Salmona form the Mario Negri Institute, IT). TREG-lipid was synthesized as previously reported Markoutsa et al., 2015; Papadia et al., 2017) . A bath sonicator (Branson) and microtip-probe sonicator (Sonics and Materials) were used for liposome preparation.
Materials & methods
1,2-Distearoyl-sn-glycerol-3-phosphatidylcholine (DSPC), 1,2- distearoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy(poly ethyleneglycol)-2000] (DSPE-PEG 2000 [PEG-lipid]), 1,2-distearoyl- sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] [PEG
Liposome preparation and physicochemical characterization
LIPs were prepared by the optimized methodology developed, and described in detail, recently (Papadia et al., 2017) . In brief, for mf-LIPs, a solution of lipids (DSPC/Chol/PEG-lipid/PEG-Mal/TREG-lipid, at 2:1:0.16:0.002 or 0.004:0.2 (mole/mole) ratios) was evaporated, forming a thin film of lipids that was hydrated (with PBS) to form a dispersion of multilamellar liposomes, and subsequently sonicated for size reduction. The TfR-Mab was thiolated, as reported in detail before Papadia et al., 2014) . For attachment of the Mab and the ApoE peptide on the liposome surface, the thiolated-TfRMab together with ApoE were co-incubated with the LIPs, at molar concentrations (compared to phospholipid) of 0.1% (MONO density) or 0.2% (DOUBLE density) overnight at 25°C. Finally, non-attached fractions of TfR-Mab and ApoE were removed from LIPs by ultracentrifugation at 40,000 rpm for 2 × 30 min. BBB-LIPs were prepared by exactly the same method without including the TREG-lipid in their lipid membrane. In both LIP types, DiR was added as a label, to assist live-animal imaging, by incorporating the dye at 0.16 mol% (of total lipid) in the liposomal lipid membrane, during the initial preparation of the thin lipid film. Liposome dispersions were sterilized by filtration through 0.22 μm sterilized filter, under laminar flow, prior to injection in mice.
DiR-LIPs were characterized for ligand attachment by: (i) fluorescence intensity (FI) measurements for quantification of the attached ApoE; (ii) an Elisa assay that was developed in order to quantify the non-attached TfR-Mab (which was proven to provide accurate estimations of the vesicle attached Mab ), and (iii) HPLC for quantification of the liposome-associated TREG-lipid. All the previous methodologies have been described in detail earlier Papadia et al., 2014 and Papadia et al., 2017) . The liposome size distribution was measured by dynamic light scattering (DLS), and their z-potential by Doppler electrophoresis, as also described in detail before (Papadia et al., 2017) .
In vivo live animal imaging and ex-vivo studies
To follow the in vivo distribution of mf-LIPs after intravenous injection, DiR was used as an ideal fluorophore for LIP labelling as previously done for the BBB-LIPs , since it is rapidly eliminated from mice following tail vein injection (Xiang et al., 2011) , as verified also by our group . The retention of DiR in the liposome bilayer (of both liposome types used herein), for prolonged time periods during incubation in presence of serum proteins was previously proven (Papadia et al., 2017) . FVB mice, purchased from Hellenic Pasteur Institute (Athens, Greece) were bred at the Center for Animal Models of Disease, University of Patras, Faculty of Medicine (Rio, Greece). These mice were chosen for their white skin and fur that permits enhanced light penetrance. Animal care and experimental procedures were approved by the Veterinary Administration Bureau of the Prefecture of Achaia, Greece, and were conducted according to European Union Directive 86/609/EEC for animal experiments (http://ec.europa.eu/ environment/chemicals/lab_animals/legislation_en.htm). Mice used for experiments were sex-, weight-(20-25 g), and age-(6-12 weeks) matched. Bio-fluorescence imaging of living mice or explanted organs (in the case of ex-vivo measurements) was done on an IVIS Lumina II imager (Perkin Elmer, Santa Clara, CA). For this, mice were anesthetized using isoflurane and serially imaged at various time-points (usually 2, 4, 8, 12 or 16, 24) post-DiR-labelled LIP injection, using excitation/emission wavelengths to detect DiR (excitation: 710-760 nm; emission: 810-875 nm). Images were acquired and analyzed using Living Image v4.2 software (Perkin Elmer, Santa Clara, CA). In detail, bodily area (brain and body) -or explanted organspecific regions of interest were created, and were superimposed over all images acquired in a uniform fashion. Subsequently, photon flux within these regions was measured, and compared between mice receiving different treatments. Identical circular ROIs for head region were used for all animals for head-DIR signal measurement. Body signal was also measured using a rectangular ROI, (same ROI for all animals). Ex vivo measurement of the DiR signal of explanted organs (brain, liver and spleen) were obtained in some cases, after the animals were euthanized (following the last imaging time point).
For each formulation tested, DiR dose signals were measured by placing the specific amount of LIPs injected (in each case) in a well of a 96-well plate and measuring the bio-fluorescence signal of the DiR in the same way as measured in the animals (identical size of ROIs were used for the different formulations). Background signals of empty wells were subtracted.
A second set of live imaging (FLI) in vivo experiments was carried out in Alzheimer's disease animal models (APP/PS1 mice) and their corresponding litter-mate wild types (WT). The double transgenic mice (APP/PS1) used in the present study incorporates a human APP construct bearing the Swedish double mutation and the exon-9-deleted PSEN1 mutation: B6·Cg-Tg (APPSwe, PSEN1dE9) 85Dbo/J (Jackson Laboratory, Bar Harbor: stock no. 005864). The genotype of the mice was previously confirmed by PCR of DNA isolated from tail biopsies (Ordóñez-Gutiérrez et al., 2015) . The mice used in this case were 10 months old, male, weighting between 20 and 25 g.
Statistical analysis
All results are expressed as mean ± SD from at least three independent experiments. The significance of variability between results from various groups was determined by two-way ANOVA (by SPSS Statistical program v.2.4, IBM).
Results

Physicochemical properties of mf-LIPs
In line with previous reports Papadia et al., 2017) , the DiR labelled BBB-LIPs and mf-LIPs, prepared for in vivo/ex vivo testing had mean diameters between 112 and 155 nm (Table 1) , depending on the number of the ligands on their surface (BBB-LIPs were always slightly smaller compared to mf-LIPs), and the surface ligand density of the two BBB-targeting ligands (i.e., LIPs with MONOdensity (0.1 mol% compared to total phospholipid) were always slightly smaller from LIPs with DOUBLE-density (0.2 mol% of total phospholipid)). As for the polydispersity indexes, they range between 0.13 and 0.21 for all LIPs used herein, implying that they are monodisperse. Zeta-potential values are always close to zero, as anticipated by the zwittero-ionic nature of their lipid components. As for the attachment yields for all three ligands attached, as reported before (Papadia et al., 2017 ) the yield for TREG-Lipid was 89.3 ± 1.2%, for Mab 67.3 ± 8.0, and for ApoE 86.7 ± 7.8.
Targeting potential of MF-LIPs compared to BBB-LIPs -live animal imaging
Serial bio-fluorescence imaging revealed that infrared-emitting DiR is an accurate technique to monitor LIP distribution after in vivo administration, compared to FITC or Rhodamine-lipid, yielding an S/N of several thousand, coupled with a satisfactory dose-response . Free DiR is rapidly eliminated from mice following tail vein injection (Xiang et al., 2011; Markoutsa et al., 2014) ; therefore free-DiR-injected controls were not included in the current studies.
Studies in FVB mice
FVB mice were randomly allocated to treatment with 0.05 or 0.15 mg liposomal lipid/mouse, via tail vein injection (n = 4-8 mice/ group). In Fig. 1 the head-signals for DiR, measured at various time points post-injection of 0.05 mg/mouse of LIPs with DOUBLE density (of the BBB specific ligands) are presented. As seen, the head-DiR signals, are higher (from 30 to 50%) after mf-LIP injection, compared to those acquired from the BBB-LIPs (Fig. 1A) . However, there is no statistical significant difference between the two distribution profiles for the time period studied (P = 0.9635), and the difference between the two types of LIPs is significant only at the 4 h time point. The same is true for the head/body signal ratios, where the ratios of the mf-LIPs are slightly higher (by 1 up to 30%) (Fig. 1B) , but again the differences are not significant (P = 0.8063). The Brain-DiR signals measured ex-vivo for each case of LIPs in the same experiment, 24 h post-injection, are seen in Fig. 2 , and as observed, the value for mf-LIPs is 26% higher than the corresponding value for BBB-LIPs, but the difference is not significant (P = 0.069). However, when the brain signals are divided with the corresponding signals measured in the liver and in the spleen, the Table 1 Physicochemical properties of mf-LIPs and BBB-LIPs (control vesicles) used in the in vivo studies. LIPs with 0.1 or 0.2 (mol%) concentration of the BBB-specific ligands were constructed and are referred to as MONO or DOUBLE, respectively. Size distribution [mean hydrodynamic diameter and polydispersity index (PI)] and zeta-potential values reported, are mean values from at least 4 different preparations.
LIP-type
Mean hydrodynamic diameter (nm)
BBB-LIPs (mono) 111.9 ± 3.8 0.172 ± 0.045 −3.01 ± 0.72 mf-LIPs (mono) 136 ± 18 0.131 ± 0.054 −3.71 ± 0.72 BBB-LIPs (double) 145 ± 13 0.205 ± 0.045 −3.35 ± 0.44 mf-LIPs (double) 155 ± 30 0.213 ± 0.055 −3.31 ± 1.51 Head and body signals were measured using the same circular or rectangular ROI for all animals, respectively. Asterisks denote significant differences as calculated by one-way ANOVA, between the two groups of animals tested in each case, at the specific time-points (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
brain / liver + spleen signal ratio of the mf-LIPs is significantly higher (by 43%), compared to that of BBB-LIPs (P b 0.001).
The head-DiR signals and the HEAD/BODY signal ratios acquired following injection of a three times higher dose (0.15 mg lipid per mouse), of mf-LIPs and BBB-LIPs with MONO, and DOUBLE surface-density (of the BBB-specific ligands), are presented in Fig. 3 . For the MONO LIPs, the head-DiR signals acquired after injection of mf-LIPs are slightly higher, compared to those measured over the same time period (0-24 h) after BBB-LIP injection (P = 0.0332). Furthermore, the differences between the two previous LIP types (mf-LIPs and BBB-LIPs) the in head/ body (signal) ratios are even more profound as seen in Fig. 3C , and the effect of LIP type in this case is highly significant (P b 0.0001). Oppositely, in the case of LIPs with DOUBLE density of BBB-specific ligands, the head-DiR signals (Fig. 3B) , as well as the head/body (signal) ratios (Fig. 3D) , are similar between mf-LIPs and BBB-LIPs (P N 0.05), indicating the importance of the surface density of ligands. Nevertheless, head-DiR signal's acquired by MONO density NLs are lower compared to those measured after administration of LIPs with DOUBLE (BBB-specific) ligand density, especially at the time points between 4 and 12 h, as seen when comparing Figs. 3A & B. The later observation suggests that when the brain-specific ligands are doubled, higher amounts of LIPs are distributed in the brain. However, when the head/body signal ratios are compared between the same two cases of LIPs (Fig. 3C & D) , it is evident that for the MONO type mf-LIPs, the fraction of LIP-associated-DiR in the head is higher compared to the corresponding DOUBLE LIP-type, due to the lower DiR-signals in the BODY of the mice injected with MONO mf-LIPs.
The ex-vivo values from the same series of experiments are shown in Fig. 4 . For all LIP-types evaluated, the brain-DiR signals (as well as the brain / liver + spleen signal ratios), are substantially lower at 24 h compared to the corresponding values at 8 h, indicating that LIPs are LIPs with DOUBLE density of the brainspecific ligands were used. Each value is the mean from 4 to 6 animals and SD value of each mean is presented as bars. Asterisks denote significant differences between the two formulations tested in each case (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). Head and Body signals were measured using the same circular or rectangular ROI for all animals, respectively. Representative images of the animals at 8 and 24 h post-injection are presented in the right side of the graph for each LIP-type injected (on the top for MONO, and on the bottom for DOUBLE LIPs). Each value is the mean from 4 to 6 animals and SD value of each mean is presented as bars. Asterisks denote significant differences between the two formulations tested in each case (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
eliminated from the brain in this time period. By comparing the two sets of results, in vivo live-imaging (Fig. 3 ) and ex-vivo (Fig. 4) , one easily sees that the mean values of ex-vivo brain-DiR signals (Fig. 4A & B) have lower variations compared to the corresponding live imaging results ( Fig. 3A & B) . The latter is most possibly attributed to the avoidance of the interference from skin differences (related to scratches or irritations) in the ex-vivo study, resulting in more accurate measurments. ANOVA comparisons of the (ex-vivo) brain / liver + spleen signal ratios for mf-LIPs and BBB-LIPs, reveals that the differences are significant for both LIP types, MONO (P = 0.0083) and DOUBLE (P = 0.0477) liposomes, although for the brain-DiR signals the differences between mfLIPs and BBB-LIPs were not significant (P N 0.05), for the specific time points (8 h and 24 h) tested.
By comparing Figs. 4A and 4B, it is seen that when the density of the BBB-specific ligands is doubled in mf-LIPs, their brain-DiR signal is significantly increased (approx. 1.9 times higher) 24 h post-injection. In fact the same is seen for the BBB-LIPs (red bars); however the effect of increasing the ligand density on the 24-h brain-DiR signal is more profound in the case of BBB-LIPs (compared to mf-LIPs), since the 24 h brain-DiR signal of DOUBLE BBB-LIPs is 2.8 times higher than MONO BBB-LIPs, revealing that the addition of TREG-lipid in the BBB-LIP membrane, influences -to some extent -the LIP (associated DiR) pharmacokinetics. The later ex-vivo results, agree with the conclusion made for the live imaging results, that the surface density of the BBB-specific ligands is an important factor that influences the effect of TREG-lipid addition (in the BBB-LIP membrane) on the biodistribution/pharmacokinetics of the LIPs.
When the head-DiR signals acquired after administration of 0.05 and 0.15 mg of lipid per mouse are compared (before normalization for DiR dose) for the mf-LIPs as well as BBB-LIPs, it is evident that as the dose increases, a relative increase is observed in the head-DiR signals (not shown). Furthermore, when the DiR-signals are normalized for the DiR dose, the values are similar between the two doses (not shown), indicating that within this specific dose range, LIP-associated-DiR follows linear pharmacokinetics, or else that the organs responsible for LIPclearance (mainly liver and spleen) are not saturated.
Studies to compare brain distribution of mf-LIPs and BBB-LIPs in APP/ PS1 and littermate mice
In another set of in vivo experiments, the head signals (Photon/s) of DiR-loaded MONO density mf-LIPs and BBB-LIPs was followed, after tail-vein injection of a high dose of LIPs (4 mg lipid/mouse) in APP/ PS1 and their litter-mates (WT); BBB-LIP brain distribution was acquired under similar conditions in FVB mice before . As seen by the results presented in Fig. 5 , in both groups of mice (double transgenic and WT) the brain-DiR signals are higher (between 2 and 2.5 times) for mf-LIPs compared to BBB-LIPs. In fact it is calculated by 2-way-ANOVA, that the effect of the different LIP type (mf-LIP and BBB-LIP) on their pharmacokinetic distribution is significant in both types of mice, APP/PS1 (P = 0.0103) and also WT (P = 0.0499), suggesting that under the specific administration conditions (MONO density LIPs, high dose) the addition of TREG-lipid in the membrane of BBB-LIPs does not decrease their distribution to the brain, but on the contrary, it enhances it. Unfortunately the body organs were not extracted at the end of this experiment; thereby we do not have any information about the liver and spleen distribution of the LIPs, in the specific animals. However, it has to be mentioned, that due to the fact that mouse skin is black, the area of the brain was shaved prior to imaging (and background values were subtracted from the signals measured at each time-point); thereby the signals measured by live-imaging should be accurate. were explanted from all mice (at 8 or 24 h post-injection) and measured for DiR FI, as described in detail in the Materials & methods section. Each value is the mean from 4 to 6 animals and SD value of each mean is presented as bars. Asterisks denote significant differences between the two formulations tested in each case (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
In the later experiment (Fig. 5) , no differences were found between the brain-DiR signals measured in APP-PS1 mice and the corresponding WT mice, when both were injected with BBB-LIPs (P = 0.1693), or mfLIPs (P = 0.0583).
In order to understand if the similar behavior between transgenic and WT mice, in the later study, is attributed to the fact that a very high dose of lipid was administered (at which the organs responsible for elimination of liposomes from the blood circulation are -most probably -saturated, and a very high concentration of LIPs is most probably present in the bloodstream), another experiment was carried out in which a dose of 0.05 mg lipid/animal (low dose) of mf-LIPs (with DOU-BLE density of BBB-specific ligands) was injected, and the brain-distributed DiR-amounts were followed for 55 h post-injection, in APP/PS1 mice and their litter mate WTs. Interestingly, as seen in Fig. 6 , under this experimental setup, the brain-DiR signals measured in APP/PS1 mice were found to be substantially higher (between 31% and 55% for the different time points reported) compared to those in the WT-mice (P = 0.0019).
The two last set of results (Figs. 5 and 6) indicate the importance of the dose administered when the brain targeting capability of LIPs in different animal models is studied by live animal imaging.
Discussion
Several types of nanoparticles have been proposed as theranostic carrier systems for AD Mourtas et al., 2014; Lazar et al., 2013; Antimisiaris et al., 2014; Ma et al., 2015) , and although some were proven to specifically interact with amyloid species and demonstrate interesting therapeutic potential (towards AD) (Balducci et al., 2014; Bana et al., 2014) , not much is known about their capability to translocate across the BBB (Koffie et al., 2011; Rotman et al., 2015a Rotman et al., , 2015b . Particularly when more than one ligands are attached on the surface of NPs, to confer different functionalities (i.e. translocation across the BBB, affinity for amyloids or other pathological features), potential interactions between the different ligands that could decrease the functionality of some (or maybe even all) of the ligands, may occur; thereby the preservation of the different functionalities on such multifunctional NPs should be exploited when particular ligands are used. In this context, multifunctional liposomes (mf-LIPs) decorated with a curcumin-lipid ligand (TREG-lipid) together with two BBB-specific ligands, were recently proven (Papadia et al., 2017) to have -at least -similar capability to translocate across the BBB (in the hCMEC/ D3 monolayer system), when compared with LIPs having only the two BBB-specific ligands, by in vitro methods, and in a preliminary in vivo study in normal mice. Herein, the same mf-LIPs are studied in vivo and ex vivo in FVB mice (normal), and in double transgenic APP/PS1 mice and litter-mate wild types (WT), in order to verify the previous in vivo findings and additionally understand the importance of experimental parameters, such as the dose administered and the surface density of the BBB-specific ligands.
The results of a series of live imaging in vivo studies in FVB mice (Figs. 1-4) , confirmed that the particular mf-LIPs have (at least) similar ability to reach the brain with the corresponding BBB-LIPs, in good agreement with the results of the in vitro studies in hCMEC/D3 cell monolayers (Papadia et al., 2017) . Interestingly, from the studies carried out in FVB mice, it is concluded that mf-LIPs with MONO-density of BBBspecific ligands on their surface, have slightly higher brain-DiR fractions (brain / liver + spleen signal ratios) due to their lower distribution in Fig. 5 . Brain-DiR signals (Photons/s) followed for up to 120 h post-injection by live animal imaging after iv injection of 4 mg lipid/mouse (high dose) of mf-LIP (hollow symbols) and BBB-LIPs (solid symbols) (both with MONO density of BBB-specific ligands). Double transgenic APP/PS1 mice (red symbols) and their litter mates (WT, black symbols) were injected with both LIP-types via tail vein. Each value is the mean from 5 to 6 animals and SD value of each mean is presented as bars. Asterisks denote significant differences as calculated by one-way ANOVA, between the two groups of animals tested in each case, at the specific time-points (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). liver and spleen, compared to the corresponding DOUBLE mf-LIPs, (Fig.  4C & D) . The later phenomenon of higher preference of DOUBLE mf-LIPs (compared to MONO mf-LIPs) for macrophage-rich organs (liver and spleen), has two possible explanations: (i) when more ligands are immobilized on the liposome surface their "stealth" characteristics are decreased, or (ii) LIPs with more BBB-specific ligands on their surface are taken up more by liver and spleen due to the expression of transferrin receptors in these organs (Lombard et al., 1989) . But when the corresponding brain-DiR signals and the brain / liver + spleen signal ratios of BBB-LIPs are compared, such difference (as those mentioned above for mf-LIP between MONO and DOUBLE) are not observed; indicating that the specific effects are not connected with the BBB-specific ligands but rather with TREG-lipid, which is only present on the mf-LIP surface. It seems that TREG-lipid reduces the fraction of LIPs distributed in the liver and spleen, and this phenomenon is more profound when the density of the BBB-specific ligands on the same vesicle is lowest (MONO density). In other words, the influence of TREG-lipid to reduce the uptake of the mf-LIPs by the RES is disturbed when the density of the BBB-specific ligands is increased (from 0.1 to 0.2 mol%). The later effect of TREG-lipid, may also be connected with the increased integrity of the TREG-lipid-incorporating liposomes (compared to BBBLIPs), when they are incubated in presence of serum proteins, as recently reported (Papadia et al., 2017) . In fact, the integrity was higher for the MONO mf-LIPs compared to the DOUBLE. It seems that perhaps the presence of TREG-lipid modulates the surface characteristics of the LIPs, preventing the adsorption of opsonins on their surface, and leading to their decreased uptake by macrophage-rich organs. It would be interesting to prove this hypothesis by protein adsorption studies, and also understand if the same effect is demonstrated when curcumin is incorporated in the liposome membranes, since liposomal curcumin has several potential applications in therapeutics (Mahmud et al., 2016; Matloob et al., 2014) . Also, it is not known if perhaps the recently demonstrated curcumin-induced suppression of macrophages and reduction of the number of macrophages (Amano et al., 2015) , is implicated in the reduced uptake of the mf-LIP by liver and spleen.
When mf-LIPs (MONO) were injected in double transgenic APP/PS1 mice and their -litter mates (WT) at a very high dose (~25 times higher than the dose administered to FVB mice), mf-LIP injection resulted in significantly higher brain signals compared to BBB-LIPs (as much as 2.5 times higher DiR-signals) (Fig. 5) ; in fact the differences between mf-LIPs and BBB-LIPs were higher than those measured in FVB mice (Fig. 3) . Since this is the case for both, double transgenic and WT mice, it cannot be attributed to any specific pathological features of the transgenic mice (i.e. increased amounts of brain amyloid deposits, increased expression of RAGE receptor, partial disruption of the BBB), so it must be related to the difference in the dose administered (high dose in APP/PS1 and WTs and low dose in FBV) or perhaps also to the different age of the animal groups (transgenic and WT mice were older than FBV mice), which may confer differences in brain amyloid loads or RAGE levels (Choi et al., 2014) . In the high-dose in vivo study, as mentioned, there was no significant difference between APP/PS1 and WT mice, indicating that the BBB of APP/PS1 is not impeded to allow higher translocation of LIPs in the brain, in good agreement with previous findings (Bien -Ly et al., 2015; Zhang et al., 2014) . However, when mf-LIPs (with DOUBLE density of BBB-ligands) were injected at a much lower dose (80 times lower) to both mouse strains, the brain-DiR signals were significantly higher in the double transgenic mice compared to the WT's (Fig. 6) . This difference could be explained by a potential impairment of the BBB in the APP/PS1 mice, however this explanation does not agree with the results of the high dose experiment (Fig. 5) . In any case, it should be considered that the brain DiR-signal followed in all the in vivo imaging studies, is attributed to the cumulative amount of dye in the bloodstream and in the brain capillaries, thereby when a very high dose of lipid is administered, the very large amount of liposomal-DiR in the circulation may perhaps be masking any difference in the fraction of liposomal-DiR translocated across the BBB and into the brain, since most probably the later fraction is a small fraction of the total dye (as explained below). Also, there is a possibility, that the transport of mf-LIPs across the BBB may be (at least partly) facilitated by the RAGE transporter (the transported responsible for Aβ peptide translocation from blood to brain), which may perhaps be up regulated in the APP/PS1 mice, compared to the WTs. The later suggestion is in good agreement with the increased uptake of TREG-NLs (compared to plain PEG-NLs) by hCMEC/D3 cells and their higher translocation across the cell monolayer, which was demonstrated before (Papadia et al., 2017) . In fact, it was recently proven, that LIPs with high affinity for amyloid species are translocated across the cellular in vitro model of the BBB at higher amounts, when the experiment is carried out in presence of Aβ peptides, by a mechanism which implicates the RAGE transporter (Markoutsa et al., 2012) .
In any case, it is not easy to clarify why the difference between transgenic and WT mice is only observed when a low lipid dose is administered, with the data currently available. Previously, the differences observed in brain levels of bifunctional anti-amyloid antibodies between different studies, have been attributed to the big differences in the doses administered (Rotman et al., 2015b) . Furthermore, there are not many studies in the literature, were AD-targeted nanotechnologies have been evaluated for their capability to reach the brain, in both transgenic and littermate mice. Indeed, in most studies, targeted NPs are compared with non-targeted ones in either WT or transgenic mice, but not in both (Koffie et al., 2011; Zhang et al., 2014) . In the study of Rotman et al. (2015a) glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment, was higher in transgenic mice compared to the WT littermates, after iv injection of a 5 μg antibody dose, which corresponds to 1.5 mg of lipid; a dose which is between the two doses used herein (low and high). As mentioned above, when very high lipid doses are administered, the organs implicated in the clearance of LIPs from blood circulation are saturated, and high fractions of vesicles are present in the blood circulation, which may potentially "cover" small differences between liposome fractions which are translocated across the BBB. Additionally, when a comparatively high dose of the mf-LIPs is administered, any potential curcumin-induced suppression and reduction of the number of macrophages in mice liver (Amano et al., 2015) , will be more pronounced, resulting in even higher than anticipated LIP concentrations in the bloodstream.
The difference between brain DiR-signals in APP/PS1 and WT mice (when low lipid-dose is injected) is not very pronounced (31-55%), indicating that even if this difference is fully attributed to a pathology-related BBB disruption in the transgenic mice, the potential disruption is not extended. The last suggestion is in line with a recent study in which the lack of widespread BBB disruption in AD models was demonstrated (Bien-Ly et al., 2015) , highlighting the urgent need for development of BBB-targeting nanotechnologies.
Conclusions
Summarizing the current in vivo studies, it is concluded that: (i) The targeting capability of mf-LIPs in normal FVB mice is proven to be at least similar to that of BBB-LIPs, verifying the recently reported results of in vitro and preliminary in vivo studies, according to which the addition of the TREG-lipid curcumin derivative in the liposome membrane does not disturb the function of the BBB-specific ligands. (ii) The addition of TREG-lipid in the BBB-LIPs results in lower fractions of LIPs in the liver and spleen following their injection in FVB mice; especially when the density of the BBB-specific ligands on the mf-LIP surface is lower (0.1%, compared to 0.2%). The later observation may be related to the recently reported curcumin-induced suppression and reduction of the number of macrophages in mice liver (Amano et al., 2015) . (iii) From the preliminary live animal imaging studies carried out in an animal model of AD (APP/PS1 mice) and littermate WT mice, it is concluded that the liposome dose administered is an important parameter, suggesting that such screening studies should preferably be carried out using different doses. Interestingly, when a low dose of liposomes was administered in both double transgenic (animal model of AD) and WT mice, significant differences in the brain targeting capability of mf-LIPs were demonstrated between WT and transgenic (APP/PS1) mice, indicating the high potential of such liposomes as theranostic systems for AD.
